ID   PLK2_HUMAN              Reviewed;         685 AA.
AC   Q9NYY3; O60679; Q96CV7; Q9UE61;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2002, sequence version 3.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Serine/threonine-protein kinase PLK2;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 2;
DE            Short=PLK-2;
DE            Short=hPlk2;
DE   AltName: Full=Serine/threonine-protein kinase SNK;
DE            Short=hSNK;
DE   AltName: Full=Serum-inducible kinase;
GN   Name=PLK2; Synonyms=SNK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=11696980; DOI=10.3109/10425170109041337;
RA   Liby K., Wu H., Ouyang B., Wu S., Chen J., Dai W.;
RT   "Identification of the human homologue of the early-growth response
RT   gene Snk, encoding a serum-inducible kinase.";
RL   DNA Seq. 11:527-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon;
RA   Anderson K.M., Nerurkar S.S., Hansbury M.J., Fornwald J., Scott G.,
RA   Bouzyk M., Mui P., Imbrugia C.S., Carlson K., Marshall L.A.,
RA   Roshak A.K.;
RT   "Identification and characterization of human serum-inducible kinase
RT   (SNK), a novel member of the polo-kinase family of cell cycle
RT   regulators: potential implication for regulation of vascular smooth
RT   muscle proliferation.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 110-408.
RA   Fidler C., Boultwood J., Wang Jabs E., Wainscoat J.S.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   INDUCTION.
RX   PubMed=11716500; DOI=10.1006/bbrc.2001.5993;
RA   Shimizu-Yoshida Y., Sugiyama K., Rogounovitch T., Ohtsuru A.,
RA   Namba H., Saenko V., Yamashita S.;
RT   "Radiation-inducible hSNK gene is transcriptionally regulated by p53
RT   binding homology element in human thyroid cells.";
RL   Biochem. Biophys. Res. Commun. 289:491-498(2001).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15242618; DOI=10.1016/j.cub.2004.06.059;
RA   Warnke S., Kemmler S., Hames R.S., Tsai H.L., Hoffmann-Rohrer U.,
RA   Fry A.M., Hoffmann I.;
RT   "Polo-like kinase-2 is required for centriole duplication in mammalian
RT   cells.";
RL   Curr. Biol. 14:1200-1207(2004).
RN   [8]
RP   DOWN-REGULATION IN B-CELL LYMPHOMAS.
RX   PubMed=16160013; DOI=10.1182/blood-2005-03-1194;
RA   Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L.,
RA   O'Nions J., Allday M., Hoffmann I., Crawford D., Griffin B.,
RA   Farrell P.J., Crook T.;
RT   "Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a
RT   frequent event in B-cell malignancies.";
RL   Blood 107:250-256(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-210; TRP-503;
RP   HIS-629 AND LYS-631.
RX   PubMed=19001868; DOI=10.4161/cc.7.22.7071;
RA   Cizmecioglu O., Warnke S., Arnold M., Duensing S., Hoffmann I.;
RT   "Plk2 regulated centriole duplication is dependent on its localization
RT   to the centrioles and a functional polo-box domain.";
RL   Cell Cycle 7:3548-3555(2008).
RN   [10]
RP   INDUCTION.
RX   PubMed=18832181; DOI=10.1073/pnas.0808266105;
RA   Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y.,
RA   Yan M., Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K.,
RA   Zhang D.E., Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R.,
RA   Rowley J.D., Chen J.;
RT   "Distinct microRNA expression profiles in acute myeloid leukemia with
RT   common translocations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:15535-15540(2008).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF CENPJ.
RX   PubMed=20531387; DOI=10.1038/emboj.2010.118;
RA   Chang J., Cizmecioglu O., Hoffmann I., Rhee K.;
RT   "PLK2 phosphorylation is critical for CPAP function in procentriole
RT   formation during the centrosome cycle.";
RL   EMBO J. 29:2395-2406(2010).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF NPM.
RX   PubMed=20352051; DOI=10.1371/journal.pone.0009849;
RA   Krause A., Hoffmann I.;
RT   "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4
RT   triggers centriole duplication.";
RL   PLoS ONE 5:E9849-E9849(2010).
RN   [13]
RP   DOWN-REGULATION IN ACUTE MYELOID LEUKEMIA.
RX   PubMed=21340720; DOI=10.1007/s00277-011-1193-4;
RA   Benetatos L., Dasoula A., Hatzimichael E., Syed N., Voukelatou M.,
RA   Dranitsaris G., Bourantas K.L., Crook T.;
RT   "Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated
RT   gene in acute myeloid leukemia and myelodysplastic syndromes: genetic
RT   and epigenetic interactions.";
RL   Ann. Hematol. 90:1037-1045(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=20671765; DOI=10.1038/nrd3184;
RA   Strebhardt K.;
RT   "Multifaceted polo-like kinases: drug targets and antitargets for
RT   cancer therapy.";
RL   Nat. Rev. Drug Discov. 9:643-660(2010).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-14; SER-92; LYS-436 AND LEU-487.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase
CC       involved in synaptic plasticity, centriole duplication and G1/S
CC       phase transition. Polo-like kinases act by binding and
CC       phosphorylating proteins are that already phosphorylated on a
CC       specific motif recognized by the POLO box domains. Phosphorylates
CC       CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a
CC       key role in synaptic plasticity and memory by regulating the Ras
CC       and Rap protein signaling: required for overactivity-dependent
CC       spine remodeling by phosphorylating the Ras activator RASGRF1 and
CC       the Rap inhibitor SIPA1L1 leading to their degradation by the
CC       proteasome. Conversely, phosphorylates the Rap activator RAPGEF2
CC       and the Ras inhibitor SYNGAP1, promoting their activity. Also
CC       regulates synaptic plasticity independently of kinase activity,
CC       via its interaction with NSF that disrupts the interaction between
CC       NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of
CC       AMPAR-mediated current that occludes long term depression.
CC       Required for procentriole formation and centriole duplication by
CC       phosphorylating CENPJ and NPM1, respectively. Its induction by
CC       p53/TP53 suggests that it may participate in the mitotic
CC       checkpoint following stress. {ECO:0000269|PubMed:15242618,
CC       ECO:0000269|PubMed:19001868, ECO:0000269|PubMed:20352051,
CC       ECO:0000269|PubMed:20531387}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by phosphorylation of Thr-239. Once
CC       activated, activity is stimulated by binding target proteins (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with NSF; causing NSF dissociation from GRIA2.
CC       Interacts with CIB1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q86Y33:CDC20B; NbExp=3; IntAct=EBI-721354, EBI-10260504;
CC       Q9HC77:CENPJ; NbExp=3; IntAct=EBI-721354, EBI-946194;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole
CC       {ECO:0000269|PubMed:15242618, ECO:0000269|PubMed:19001868}. Cell
CC       projection, dendrite {ECO:0000250}. Note=Localizes to centrosomes
CC       during early G1 phase where it only associates to the mother
CC       centriole and then distributes equally to both mother and daughter
CC       centrioles at the onset of S phase.
CC   -!- TISSUE SPECIFICITY: Expressed at higher level in the fetal lung,
CC       kidney, spleen and heart. {ECO:0000269|PubMed:11696980}.
CC   -!- INDUCTION: Directly regulated by p53/TP53. Negatively regulated by
CC       miR-126. {ECO:0000269|PubMed:11716500,
CC       ECO:0000269|PubMed:18832181}.
CC   -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module
CC       that recognize and bind serine-[phosphothreonine/phosphoserine]-
CC       (proline/X) motifs. PLK2 recognizes and binds docking proteins
CC       that are already phosphorylated on these motifs, and then
CC       phosphorylates them (By similarity). {ECO:0000250}.
CC   -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-239.
CC       {ECO:0000250}.
CC   -!- MISCELLANEOUS: There are indications that PLK2 might act as a
CC       tumor suppressor: PLK2 is significantly down-regulated in a wide
CC       range of acute myeloid leukemias (AMLs) and B-cell lymphomas due
CC       to aberrant cytosine methylation in the CpG island located at the
CC       5' of the PLK2 gene (PubMed:16160013, PubMed:21340720). Moreover,
CC       miR-126, a microRNA that negatively regulates PLK2 is up-regulated
CC       in AMLs, suggesting that PLK2 down-regulation by miR-126 could
CC       also contribute to leukemogenesis (PubMed:18832181).
CC       {ECO:0000305|PubMed:16160013, ECO:0000305|PubMed:18832181,
CC       ECO:0000305|PubMed:21340720}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF059617; AAC14573.1; -; mRNA.
DR   EMBL; AF223574; AAF62897.1; -; mRNA.
DR   EMBL; U85755; AAD00575.1; -; mRNA.
DR   EMBL; AC008814; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC013879; AAH13879.1; -; mRNA.
DR   CCDS; CCDS3974.1; -.
DR   RefSeq; NP_001239155.1; NM_001252226.1.
DR   RefSeq; NP_006613.2; NM_006622.3.
DR   UniGene; Hs.398157; -.
DR   PDB; 4I5M; X-ray; 1.80 A; A=57-360.
DR   PDB; 4I5P; X-ray; 1.74 A; A=57-360.
DR   PDB; 4I6B; X-ray; 1.80 A; A=57-360.
DR   PDB; 4I6F; X-ray; 2.90 A; A=57-360.
DR   PDB; 4I6H; X-ray; 1.91 A; A=57-360.
DR   PDB; 4RS6; X-ray; 2.60 A; A/B=451-685.
DR   PDB; 4XB0; X-ray; 2.70 A; A/B=468-685.
DR   PDBsum; 4I5M; -.
DR   PDBsum; 4I5P; -.
DR   PDBsum; 4I6B; -.
DR   PDBsum; 4I6F; -.
DR   PDBsum; 4I6H; -.
DR   PDBsum; 4RS6; -.
DR   PDBsum; 4XB0; -.
DR   ProteinModelPortal; Q9NYY3; -.
DR   SMR; Q9NYY3; -.
DR   BioGrid; 115988; 47.
DR   DIP; DIP-48943N; -.
DR   IntAct; Q9NYY3; 23.
DR   MINT; MINT-1397390; -.
DR   STRING; 9606.ENSP00000274289; -.
DR   BindingDB; Q9NYY3; -.
DR   ChEMBL; CHEMBL5938; -.
DR   GuidetoPHARMACOLOGY; 2169; -.
DR   iPTMnet; Q9NYY3; -.
DR   PhosphoSitePlus; Q9NYY3; -.
DR   BioMuta; PLK2; -.
DR   DMDM; 22096374; -.
DR   MaxQB; Q9NYY3; -.
DR   PaxDb; Q9NYY3; -.
DR   PeptideAtlas; Q9NYY3; -.
DR   PRIDE; Q9NYY3; -.
DR   DNASU; 10769; -.
DR   Ensembl; ENST00000274289; ENSP00000274289; ENSG00000145632.
DR   GeneID; 10769; -.
DR   KEGG; hsa:10769; -.
DR   UCSC; uc003jrn.4; human.
DR   CTD; 10769; -.
DR   DisGeNET; 10769; -.
DR   GeneCards; PLK2; -.
DR   HGNC; HGNC:19699; PLK2.
DR   HPA; CAB009624; -.
DR   HPA; HPA069329; -.
DR   MIM; 607023; gene.
DR   neXtProt; NX_Q9NYY3; -.
DR   OpenTargets; ENSG00000145632; -.
DR   PharmGKB; PA134940798; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   eggNOG; ENOG410XQBP; LUCA.
DR   GeneTree; ENSGT00530000062954; -.
DR   HOGENOM; HOG000248546; -.
DR   HOVERGEN; HBG001843; -.
DR   InParanoid; Q9NYY3; -.
DR   KO; K08861; -.
DR   OMA; NGTHMSL; -.
DR   OrthoDB; EOG091G0D89; -.
DR   PhylomeDB; Q9NYY3; -.
DR   TreeFam; TF101089; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   SignaLink; Q9NYY3; -.
DR   SIGNOR; Q9NYY3; -.
DR   GeneWiki; PLK2; -.
DR   GenomeRNAi; 10769; -.
DR   PRO; PR:Q9NYY3; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000145632; -.
DR   CleanEx; HS_PLK2; -.
DR   ExpressionAtlas; Q9NYY3; baseline and differential.
DR   Genevisible; Q9NYY3; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005622; C:intracellular; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043008; F:ATP-dependent protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0060292; P:long term synaptic depression; ISS:UniProtKB.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; ISS:UniProtKB.
DR   GO; GO:0007052; P:mitotic spindle organization; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0061000; P:negative regulation of dendritic spine development; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032486; P:Rap protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0046599; P:regulation of centriole replication; IDA:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   CDD; cd13118; POLO_box_1; 1.
DR   CDD; cd13117; POLO_box_2; 1.
DR   Gene3D; 3.30.1120.30; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033701; POLO_box_1.
DR   InterPro; IPR033695; POLO_box_2.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell projection; Complete proteome;
KW   Cytoplasm; Cytoskeleton; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor.
FT   CHAIN         1    685       Serine/threonine-protein kinase PLK2.
FT                                /FTId=PRO_0000086561.
FT   DOMAIN       82    334       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      510    573       POLO box 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   DOMAIN      606    677       POLO box 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   NP_BIND      88     96       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS     57     64       Poly-His.
FT   ACT_SITE    205    205       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     111    111       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     239    239       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P53351}.
FT   VARIANT      14     14       S -> T (in an ovarian Endometrioid
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041023.
FT   VARIANT      92     92       G -> S (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041024.
FT   VARIANT     436    436       E -> K (in dbSNP:rs55768901).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041025.
FT   VARIANT     487    487       P -> L (in dbSNP:rs55645589).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041026.
FT   MUTAGEN     210    210       N->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19001868}.
FT   MUTAGEN     503    503       W->F: Impairs localization to the
FT                                centrosome and centriole duplication;
FT                                when associated with A-629 and M-631.
FT                                {ECO:0000269|PubMed:19001868}.
FT   MUTAGEN     629    629       H->A: Impairs localization to the
FT                                centrosome and centriole duplication;
FT                                when associated with F-503 and M-631.
FT                                {ECO:0000269|PubMed:19001868}.
FT   MUTAGEN     631    631       K->M: Impairs localization to the
FT                                centrosome and centriole duplication;
FT                                when associated with F-503 and A-631.
FT                                {ECO:0000269|PubMed:19001868}.
FT   CONFLICT     28     28       A -> G (in Ref. 1; AAC14573).
FT                                {ECO:0000305}.
FT   STRAND       72     74       {ECO:0000244|PDB:4I5P}.
FT   TURN         76     78       {ECO:0000244|PDB:4I5P}.
FT   STRAND       81     91       {ECO:0000244|PDB:4I5P}.
FT   STRAND       94    101       {ECO:0000244|PDB:4I5P}.
FT   TURN        102    105       {ECO:0000244|PDB:4I5P}.
FT   STRAND      106    114       {ECO:0000244|PDB:4I5P}.
FT   HELIX       115    118       {ECO:0000244|PDB:4I5P}.
FT   HELIX       121    134       {ECO:0000244|PDB:4I5P}.
FT   STRAND      145    150       {ECO:0000244|PDB:4I5P}.
FT   STRAND      152    159       {ECO:0000244|PDB:4I5P}.
FT   HELIX       167    174       {ECO:0000244|PDB:4I5P}.
FT   HELIX       179    198       {ECO:0000244|PDB:4I5P}.
FT   HELIX       208    210       {ECO:0000244|PDB:4I5P}.
FT   STRAND      211    213       {ECO:0000244|PDB:4I5P}.
FT   STRAND      219    221       {ECO:0000244|PDB:4I5P}.
FT   HELIX       224    226       {ECO:0000244|PDB:4I5M}.
FT   TURN        233    235       {ECO:0000244|PDB:4I5P}.
FT   HELIX       249    252       {ECO:0000244|PDB:4I5P}.
FT   HELIX       259    275       {ECO:0000244|PDB:4I5P}.
FT   HELIX       286    288       {ECO:0000244|PDB:4I5P}.
FT   HELIX       289    293       {ECO:0000244|PDB:4I5P}.
FT   HELIX       305    314       {ECO:0000244|PDB:4I5P}.
FT   HELIX       319    321       {ECO:0000244|PDB:4I5P}.
FT   HELIX       325    329       {ECO:0000244|PDB:4I5P}.
FT   HELIX       332    335       {ECO:0000244|PDB:4I5P}.
FT   HELIX       345    348       {ECO:0000244|PDB:4I5P}.
FT   HELIX       471    485       {ECO:0000244|PDB:4RS6}.
FT   STRAND      490    492       {ECO:0000244|PDB:4XB0}.
FT   STRAND      504    510       {ECO:0000244|PDB:4RS6}.
FT   TURN        511    514       {ECO:0000244|PDB:4RS6}.
FT   STRAND      515    520       {ECO:0000244|PDB:4RS6}.
FT   STRAND      525    529       {ECO:0000244|PDB:4RS6}.
FT   STRAND      534    537       {ECO:0000244|PDB:4RS6}.
FT   STRAND      541    547       {ECO:0000244|PDB:4RS6}.
FT   STRAND      553    558       {ECO:0000244|PDB:4RS6}.
FT   HELIX       563    582       {ECO:0000244|PDB:4RS6}.
FT   STRAND      602    616       {ECO:0000244|PDB:4RS6}.
FT   STRAND      621    625       {ECO:0000244|PDB:4RS6}.
FT   TURN        626    628       {ECO:0000244|PDB:4RS6}.
FT   STRAND      631    646       {ECO:0000244|PDB:4RS6}.
FT   STRAND      652    656       {ECO:0000244|PDB:4RS6}.
FT   HELIX       657    663       {ECO:0000244|PDB:4RS6}.
FT   HELIX       667    680       {ECO:0000244|PDB:4RS6}.
SQ   SEQUENCE   685 AA;  78237 MW;  6429F6EFD830B333 CRC64;
     MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ VPPAAPHHHH
     HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT DLTNNKVYAA KIIPHSRVAK
     PHQREKIDKE IELHRILHHK HVVQFYHYFE DKENIYILLE YCSRRSMAHI LKARKVLTEP
     EVRYYLRQIV SGLKYLHEQE ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI
     CGTPNYLSPE VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
     SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT VPDFHLSSPA
     KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH DLKKTSITQQ PSKHRTDEEL
     QPPTTTVARS GTPAVENKQQ IGDAIRMIVR GTLGSCSSSS ECLEDSTMGS VADTVARVLR
     GCLENMPEAD CIPKEQLSTS FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD
     KKTVHYYAEL GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
     YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR ISTTFRLTTL
     LMSGCSSELK NRMEYALNML LQRCN
//
